Skip to main content

Dr. Bryan A. Sisk, MD

Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)

At a glance

Years since graduation
13
In the NPI registry since
2013

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2013Medical school: Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University
  • 2013Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Pediatric Hematology & Oncology Physician primary
    MO license 2016010209
  • Pediatrics Physician
    MO license 2016010209

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Pediatric Hematology & Oncology per capita by county →

Where they work

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Vijoice (alpelisib)12

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 1 companies reported 3 payments worth $2,401 in total to this clinician.

By type
Consulting Fee$2,240
Food and Beverage$161

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
May 7, 2025Novartis Pharmaceuticals Corporation
May 7, 2025
Consulting Fee
VIJOICE · Oncology
$2,240

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Missouri →

Industry-funded research

Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $1,175,237 in research payments for these studies, mostly to the institutions running them.

  • EPIK-L1: a phase II/III double-blind, randomized, placebo-controlled study to assess the efficacy, safety and pharmacokinetics of alpelisib in pediatric and adult patients with lymphatic malformations associated with …
    Novartis Pharmaceuticals Corporation
  • EPIK-P2: A Phase II Double-blind Study With an Upfront, 16-week Randomized, Placebo-controlled Period, to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK…
    Novartis Pharmaceuticals Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Pediatric Hematology & Oncology clinicians in Saint Louis

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 17, 2025), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1073953667. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.